Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease

Biologics: Targets and Therapy

Volumn 1, Issue 1, 2007, Pages 59-68

  Barabas, Arpad Z ^a   Cole, Chad D ^b   Barabas, Arpad D ^a   Lafreniere, Rene ^a  

^a Health Sciences Centre Calgary   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody information transfer; Autoimmune disease; Immune complex; Modified vaccination technique; Prophylactic; Therapeutic

Indexed keywords

EID: 67349231457     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Andre FE. 2003. Vaccinology: past achievements, present roadblocks and future promises. Vaccine, 21:593-5.
2. Andres G, Brentjens JR, Caldwell PR, et al. 1986. Formation of immune deposits and disease. Lab Invest, 55:510-20.
3. Avrameas S. 1991. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today, 12:154-9.
4. Baker PJ, Ochi RF, Schulze M, et al. 1989. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol, 135:185-94.
5. Barabas AZ, Cole CD, Barabas AD, et al. 2006a. Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int, 56:516-29.
6. Barabas AZ, Cole CD, Barabas AD, et al. 2006b. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol, 13:17-24.
7. Barabas AZ, Cole CD, Barabas AD, et al. 2004a. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol, 85:201-12.
8. Barabas AZ, Cole CD, Barabas AD, et al. 2003. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol, 84:245-58.
9. Barabas AZ, Cole CD, Barabas AD, et al. 2004b. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol, 85:321-34.
10. Barabas AZ, Cole CD, Barabas AD, et al. 2004c. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol, 85:277-85.
11. Barabas AZ, Cole CD, Barabas AD, et al. 2006c. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int, 56:181-90.
12. Barabas AZ, James K, Lannigan R. 1969. Preliminary observations on the effect of heterologous anti-lymphocytic globulin on autologous immune complex nephritis in rats. Clin Exp Immunol, 5:419-27.
13. Barabas AZ, Lafreniere R. 2005. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev, 4:565-70.
14. Barabas AZ, Lannigan R. 1969. Auto-immune nephritis in rats. J Pathol, 97:537-43.
15. Barabas AZ, Nagi AH, Lannigan R, et al. 1970. The effect of cortisone treatment on autologous immune complex glomerulonephritis in rats. Br J Exp Pathol, 51:541-6.
16. Ben Yehuda O, Tomer Y, Shoenfeld Y. 1988. Advances in therapy of autoimmune diseases. Semin Arthritis Rheum, 17:206-20.
17. Bilsborough J, Viney JL. 2002. Getting to the guts of immune regulation. Immunology, 106:139-43.
18. Bolton WK, Spargo BA, Lewis EJ. 1974. Chronic autologous immune complex glomerulopathy: effect of cyproheptadine. J Lab Clin Med, 83:695-704.
19. Casali P, Notkins AL. 1989. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today, 10:364-8.
20. Cattran DC. 1988. Effect of ciclosporin on active Heymann nephritis. Nephron, 48:142-8.
21. Chen ZJ, Wheeler J, Notkins AL. 1995. Antigen-binding B cells and polyreactive antibodies. Eur J Immunol, 25:579-86.
22. Clynes R. 2005. Immune complexes as therapy for autoimmunity. J Clin Invest, 115:25-7.
23. Cornish J, Barabas AZ, Lannigan R. 1984. Modified immunofluorescent antibody test: demonstration of nephritogenic antigen in glomeruli of rats. Diagn Immunol, 2:133-6.
24. Coutinho A, Kazatchkine MD, Avrameas S. 1995. Natural autoantibodies. Curr Opin Immunol, 7:812-8.
25. Drakesmith H, Chain B, Beverley P. 2000. How can dendritic cells cause autoimmune disease? Immunol Today, 21:214-17.
26. Elson CJ, Weir DM. 1967. Chemotaxis of polymorphs induced by tissue antigens and normal serum in rats: a possible clearance mechanism. Clin Exp Immunol, 2:581-8.
27. Faria AM, Weiner HL. 1999. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol, 73:153-264.
28. Fujinami RS, Oldstone MB. 1985. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science, 230:1043-5.
29. Garza KM, Chan SM, Suri R, et al. 2000. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med, 191:2021-7.
30. Golbus J, McCune WJ. 1994. Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am, 20:213-42.
31. Grabar P. 1965. Some considerations of the problem of auto-antibody formation. Tex Rep Biol Med, 23:278-84.
32. Grabar P. 1983. Autoantibodies and the physiological role of immunoglobulins. Immunol Today, 4:337-40.
33. Guilherme L, Kalil J. 2004. Rheumatic fever: how streptococcal throat infection triggers an autoimmune disease. In: Rose NR, Shoenfeld Y, ed. Infection and autoimmunity. Amsterdam: Elsevier B.V. p 321-31.
34. Hasegawa Y, Kaneoka H, Tanaka T, et al. 2001. Suppression of experimental membranous glomerulonephritis in rats by an anti-MHC class II antibody. Nephron, 88:233-40.
35. Heymann W, Hackel DB, Harwood S, et al. 1959. Production of the nephritic syndrome in rat by Freund's adjuvant and rat kidney suspension. Proc Soc Exp Biol Med, 100:660-4.
36. Kerjaschki D, Farquhar MG. 1983. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med, 157:667-86.
37. Kupor LR, Lowance DC, McPhaul JJ, Jr. 1976. Single and multiple drug therapy in autologous immune complex nephritis in rats. J Lab Clin Med, 87:27-36.
38. Lafaille JJ, Mathis D. 2002. Immunological Yin-Yang. Curr Opin Immunol, 14:741-3.
39. Lenz DC, Lu L, Conant SB, et al. 2001. A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol, 167:1803-8.
40. Lernmark A. 2001. Autoimmune diseases: are markers ready for prediction? J Clin Invest, 108:1091-6.
41. Ludewig B, Junt T, Hengartner H, et al. 2001. Dendritic cells in autoimmune diseases. Curr Opin Immunol, 13:657-62.
42. Makker SP, Singh AK. 1982. Biochemical analysis of nephritogenic rat kidney tubular membrane fraction (FX1A) [abstract]. Federation of American Societies for Experimental Biology 66th Annual Meeting New Orleans, Louisiana, April 15-23, 1982, 41:1159.
43. Maloney DG, Smith B, Rose A. 2002. Rituximab: mechanism of action and resistance. Semin Oncol, 29:2-9.
44. Manz RA, Arce S, Cassese G, et al. 2002. Humoral immunity and long-lived plasma cells. Curr Opin Immunol, 14:517-21.
45. Matsukawa W, Hara S, Yoshida F, et al. 1992. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. J Lab Clin Med, 119:116-23.
46. Melief CJ, Van Der Burg SH, Toes RE, et al. 2002. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev, 188:177-82.
47. Mendrick DL, Noble B, Brentjens JR, et al. 1980. Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int, 18:328-43.
48. Morris EC, Bendle GM, Stauss HJ. 2003. Prospects for immunotherapy of malignant disease. Clin Exp Immunol, 131:1-7.
49. Nawata Y, Stall AM, Herzenberg LA, et al. 1990. Surface immunoglobulin ligands and cytokines differentially affect proliferation and antibody production by human CD5+ and CD5- B lymphocytes. Int Immunol, 2:603-14.
50. Peakman M, Dayan CM. 2001. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology, 104:361-6.
51. Penny MJ, Boyd RA, Hall BM. 1998. Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis. J Exp Med, 188:1775-84.
52. Pinckard RN, Weir DM. 1966. Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol, 1:33-43.
53. Polakis P. 2005. Arming antibodies for cancer therapy. Curr Opin Pharmacol, 5:382-7.
54. Ramiya VK, Lan MS, Wasserfall CH, et al. 1997. Immunization therapies in the prevention of diabetes. J Autoimmun, 10:287-92.
55. Reed SG, Campos-Neto A. 2003. Vaccines for parasitic and bacterial diseases. Curr Opin Immunol, 15:456-60.
56. Rich MW. 1996. Drug-induced lupus. The list of culprits grows. Postgrad Med, 100:299-8.
57. Schijns VE. 2001. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol, 21:75-85.
58. Schoen RT, Trentham DE. 1981. Drug-induced lupus: an adjuvant disease? Am J Med, 71:5-8.
59. Sherman LA. 2001. Greater complexity, greater opportunity. Curr Opin Immunol, 13:637-8.
60. Singh AK, Makker SP. 1986. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology, 57:467-72.
61. Singh AK, Schwartz MM. 1986. Circulatory antigen of Heymann nephritis. II. Isolation of a 70,000 MW antigen from normal rat serum which crossreacts with Heymann nephritis antigen. Immunology, 59:451-8.
62. Slingluff CL, Jr., Speiser DE. 2005. Progress and controversies in developing cancer vaccines. J Transl Med, 3:18.
63. Solvason N, Chen X, Shu F, et al. 1992. The fetal omentum in mice and humans. A site enriched for precursors of CD5 B cells early in development. Ann N Y Acad Sci, 651:10-20.
64. Spicer ST, Ha H, Boyd RA, et al. 2001. Il-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cells. J Immunol, 167:3725-33.
65. Stauss HJ. 2001. Benign autoimmunity to combat malignancy. Clin Exp Immunol, 125:1-2.
66. Tang Q, Bluestone JA. 2006. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev, 212:217-37.
67. Theofilopoulos AN. 1995. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today, 16:90-8.
68. Totoritis MC, Rubin RL. 1985. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med, 78:149-61.
69. Tung KS. 1994. Mechanism of self-tolerance and events leading to autoimmune disease and autoantibody response. Clin Immunol Immunopathol, 73:275-82.
70. Weigle WO, Nakamura RM, Spiegelberg HL, et al. 1967. Autoimmunity and termination of immunological unresponsiveness. Arch Pathol, 84:647-58.
71. Weiner HL. 1997. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today, 18:335-43.
72. Weiner HL. 2000. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest, 106:935-7.
73. Weir DM. 1966. The immune response after tissue injury. Pathol Eur, 1:108-18.
74. Weir DM. 1969. Altered antigens and autoimmunity. Vox Sang, 16:304-13.
75. Weir DM, Elson CJ. 1969. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum, 12:254-60.
76. Weir DM, Pinckard RN, Elson CJ, et al. 1966. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol, 1:433-42.
77. Wilson C, Tiwana H, Ebringer A. 2000. Molecular mimicry between HLA-DR alleles associated with rheumatoid arthritis and Proteus mirabilis as the Aetiological basis for autoimmunity. Microbes Infect, 2:1489-96.
78. Wucherpfennig KW. 2001. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest, 108:1097-104.
79. Yokoyama H, Goshima S, Wada T, et al. 1999. The shortand long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant, 14:2379-86.
80. Yung RL, Johnson KJ, Richardson BC. 1995. New concepts in the pathogenesis of drug-induced lupus. Lab Invest, 73:746-59.
81. Yung RL, Richardson BC. 1994. Drug-induced lupus. Rheum Dis Clin North Am, 20:61-86.